Hepatitis B Virus Promotes Proliferation and Metastasis in Male Chinese Hepatocellular Carcinoma Patients Through the LEF-1/miR-371a-5p/SRCIN1/pleiotrophin/Slug Pathway
Overview
Authors
Affiliations
Hepatocellular carcinoma (HCC) is a male-dominant cancer. Several factors may contribute to the gender difference. Recent investigations have reported that miRNAs are involved in sex-linked signaling pathways and play a critical role in the molecular pathogenesis of hepatitis B virus (HBV)-related HCC. Therefore, we speculated that some of these miRNAs might contribute to the gender differences observed in HBV-related HCC. Our results showed that miR-371a-5p was significantly upregulated in tumor tissue and serum from HCC patients and that the expression level of miR-371a-5p was related to HBV infection, sexuality, TNM stage, adjacent organ invasion and microvascular invasion. Moreover, a high level of miR-371a-5p expression predicted poor overall survival of HCC patients, and in vitro and in vivo studies revealed that the overexpression of miR-371a-5p promoted proliferation and metastasis. Mechanistic investigations suggested that miR-371a-5p was upregulated by HBV and testosterone through LEF-1. SRCIN1 was a direct target of miR-371a-5p and reversed the effects of miR-371a-5p on HCC tumorigenesis. Our results also revealed that SRCIN1 negatively regulated the expression of PTN by inhibiting the activity of NF-κB. As a hepatocyte growth factor, PTN promoted EMT-induced metastasis in vitro and in vivo through the AKT/Slug pathway. These data strongly suggested that the upregulation of miR-371a-5p played an important role in HBV-related HCC. Through the LEF-1/miR-371a-5p/SRCIN1/PTN/Slug pathway, HBV and testosterone promote the proliferation and metastasis of hepatoma cells, especially in male patients with HBV-related HCC.
miR-644a is a tumor cell-intrinsic mediator of sex bias in glioblastoma.
Hong E, Wang S, Ponti A, Hajdari N, Lee J, Mulkearns-Hubert E Neurooncol Adv. 2024; 6(1):vdae183.
PMID: 39582810 PMC: 11582885. DOI: 10.1093/noajnl/vdae183.
Yang J, Su Y, Wang Y, Gao K, Li C, Li M SAGE Open Med. 2024; 12:20503121241289290.
PMID: 39526092 PMC: 11549703. DOI: 10.1177/20503121241289290.
Zhang M, Yuan Y, Liu L, Wei Y, Yin W, Zheng L World J Gastroenterol. 2023; 29(31):4706-4735.
PMID: 37664153 PMC: 10473924. DOI: 10.3748/wjg.v29.i31.4706.
Gender Differences and miRNAs Expression in Cancer: Implications on Prognosis and Susceptibility.
Caserta S, Gangemi S, Murdaca G, Allegra A Int J Mol Sci. 2023; 24(14).
PMID: 37511303 PMC: 10380791. DOI: 10.3390/ijms241411544.
Lin C, Chen Y, Zhang F, Zhu P, Yu L, Chen W Gut Pathog. 2023; 15(1):26.
PMID: 37259127 PMC: 10230711. DOI: 10.1186/s13099-023-00554-z.